Takeda: Hemophilia A trials

The registry lists 60 Hemophilia A studies with Takeda as lead sponsor. 0 are open to participants now and 34 have results posted.

Phase 1 6Phase 2 10Phase 3 25Phase 4 9No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Phase 3Results posted
• A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX InfusionsCompletedNCT05437211Not applicableResults posted
• A Study of ADVATE in People With Hemophilia A in IndiaCompletedNCT04985682Phase 4Results posted
• A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.CompletedNCT04941898Results posted
• Study of TAK-672 in Participants With Acquired Hemophilia ACompletedNCT04580407Phase 2/3Results posted
• A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsTerminatedNCT04394286Phase 1/2Results posted
• RIXUBIS PMS India (RIXUBIS PMS)CompletedNCT03565237Phase 4Results posted
• A Study of BAX 888 in Male Adults With Severe Hemophilia ACompletedNCT03370172Phase 1/2Results posted
• ADYNOVATE Drug Use-Results SurveyCompletedNCT03169972Results posted
• BAX 802 in CHA With InhibitorsTerminatedNCT02895945Phase 3Results posted
• FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)CompletedNCT02764489Phase 3Results posted
• BAX 826 Dose-Escalation Safety StudyCompletedNCT02716194Phase 1Results posted
• A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia ACompletedNCT02615691Phase 3Results posted
• BAX 855 PK-guided DosingCompletedNCT02585960Phase 3Results posted
• BAX 855 Pediatric StudyCompletedNCT02210091Phase 3Results posted
• BAX 855 ContinuationCompletedNCT01945593Phase 3Results posted
• Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical ProceduresCompletedNCT01913405Phase 3Results posted
• Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand RegimenCompletedNCT01757405Phase 3Results posted
• Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)CompletedNCT01736475Phase 2/3Results posted
• BAX 326 Surgery Study in Hemophilia B PatientsCompletedNCT01507896Phase 3Results posted
• BAX 326 Pediatric StudyCompletedNCT01488994Phase 2/3Results posted
• Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia ATerminatedNCT01434511Phase 3Results posted
• Early Prophylaxis Immunologic Challenge (EPIC) StudyTerminatedNCT01376700Phase 3Results posted
• BAX 326 (rFIX) Continuation StudyCompletedNCT01286779Phase 3Results posted
• Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia ACompletedNCT01178294Phase 2/3Results posted
• Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B PatientsCompletedNCT01174446Phase 3Results posted
• Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for InjectionCompletedNCT00952822Phase 1Results posted
• Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia ACompletedNCT00916032Phase 4Results posted
• Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer InhibitorCompletedNCT00851721Phase 3Results posted
• Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia ACompletedNCT00666406Phase 4Results posted
• Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic SurgeryCompletedNCT00357656Phase 4Results posted
• Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedNCT00289536Phase 4Results posted
• Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedNCT00243386Phase 4Results posted
• Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A PatientsCompletedNCT00157157Phase 3Results posted
• A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia ACompletedNCT04953000
• A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to AdynovateCompletedNCT04876365
• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia AActive, not recruitingNCT04158934
• Post Marketing Surveillance Study for ADYNOVATE in South KoreaCompletedNCT03824522
• Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life PracticeCompletedNCT03199794
• Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe HemophiliaCompletedNCT03185897
• Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator InterviewsCompletedNCT03054389
• Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South KoreaCompletedNCT02922231
• GAS-Hem Feasibility StudyCompletedNCT02674997
• Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia ACompletedNCT02634723
• Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia ACompletedNCT02610127
• Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBISCompletedNCT02190149
• China ADVATE PTP StudyCompletedNCT02170402Phase 4
• ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)CompletedNCT02093741
• ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)CompletedNCT02078427
• Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodiesNo longer availableNCT01968655
• BAX 855 Dose-Escalation Safety StudyCompletedNCT01599819Phase 1
• Osteoporosis and MRI Study in HemophiliaTerminatedNCT01460147Not applicable
• First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia PatientsTerminatedNCT01191372Phase 1
• IMMUNINE Pre-Treatment StudyCompletedNCT01128881Phase 4
• ADVATE Post Authorization Safety SurveillanceCompletedNCT00214734
• Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101CompletedNCT00189982Phase 2/3
• Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A PatientsCompletedNCT00162019Phase 3
• Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedNCT00157105Phase 2/3
• Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedNCT00157053Phase 2/3
• Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia ACompletedNCT00157040Phase 2/3